Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
Background: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. Tafamidis is a kinetic stabilizer of TTR that inhibits misfolding and amyloid formation. Methods: In this post hoc analysis, dat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-09-01
|
| Series: | Clinical Medicine Insights: Cardiology |
| Online Access: | https://doi.org/10.1177/1179546817730322 |